Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROSETTA Lung-220: Pumitamig in Early-Stage NSCLC
NCT07871214Phase 2Not yet recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2026
- Primary completion
- Mar 2028
- Countries
- 14
01
Overview
A Phase 2 trial of pumitamig in non-small cell lung cancer (NSCLC), sponsored by Bristol Myers Squibb. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
pumitamig
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07871214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07871214.